These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 29653742)

  • 1. Neurocognitive correlates of medication-induced addictive behaviours in Parkinson's disease: A systematic review.
    Dawson A; Dissanayaka NN; Evans A; Verdejo-Garcia A; Chong TTJ; Frazzitta G; Ferrazzoli D; Ortelli P; Yücel M; Carter A
    Eur Neuropsychopharmacol; 2018 May; 28(5):561-578. PubMed ID: 29653742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Hypothesis: Parkinson's disease, reward deficiency syndrome and addictive effects of levodopa].
    Linazaroso G; van Blercom N; Lasa A
    Neurologia; 2004 Apr; 19(3):117-27. PubMed ID: 15088161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Iowa Gambling Task in Parkinson's disease: A meta-analysis on effects of disease and medication.
    Evens R; Hoefler M; Biber K; Lueken U
    Neuropsychologia; 2016 Oct; 91():163-172. PubMed ID: 27475264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive impulsivity in Parkinson's disease patients: assessment and pathophysiology.
    Robert G; Drapier D; Verin M; Millet B; Azulay JP; Blin O
    Mov Disord; 2009 Dec; 24(16):2316-27. PubMed ID: 19908312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gambling behavior in Parkinson's Disease: Impulsivity, reward mechanism and cortical brain oscillations.
    Balconi M; Angioletti L; Siri C; Meucci N; Pezzoli G
    Psychiatry Res; 2018 Dec; 270():974-980. PubMed ID: 29580652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel, Expert-Endorsed, Neurocognitive Digital Assessment Tool for Addictive Disorders: Development and Validation Study.
    Lee RSC; Albertella L; Christensen E; Suo C; Segrave RA; Brydevall M; Kirkham R; Liu C; Fontenelle LF; Chamberlain SR; Rotaru K; Yücel M
    J Med Internet Res; 2023 Aug; 25():e44414. PubMed ID: 37624635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anhedonia in Parkinson's disease patients with and without pathological gambling: a case-control study.
    Pettorruso M; Martinotti G; Fasano A; Loria G; Di Nicola M; De Risio L; Ricciardi L; Conte G; Janiri L; Bentivoglio AR
    Psychiatry Res; 2014 Feb; 215(2):448-52. PubMed ID: 24373553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of dopamine and clinical heterogeneity in cognitive dysfunction in Parkinson's disease.
    Cools R; Tichelaar JG; Helmich RCG; Bloem BR; Esselink RAJ; Smulders K; Timmer MHM
    Prog Brain Res; 2022; 269(1):309-343. PubMed ID: 35248200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Imaging of Addictive Behavior in Idiopathic Parkinson's Disease.
    Ghadery C; Valli M; Mihaescu A; Strafella R; Navalpotro I; Kim J; Strafella AP
    Int Rev Neurobiol; 2018; 141():365-404. PubMed ID: 30314604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychogenic and neural visual-cue response in PD dopamine dysregulation syndrome.
    Loane C; Wu K; O'Sullivan SS; Lawrence AD; Woodhead Z; Lees AJ; Piccini P; Politis M
    Parkinsonism Relat Disord; 2015 Nov; 21(11):1336-41. PubMed ID: 26427639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Personality Traits and Cortical Activity Affect Gambling Behavior in Parkinson's Disease.
    Balconi M; Siri C; Meucci N; Pezzoli G; Angioletti L
    J Parkinsons Dis; 2018; 8(2):341-352. PubMed ID: 29614700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognitive states influence dopamine-driven aberrant learning in Parkinson's disease.
    Cavanagh JF; Mueller AA; Brown DR; Janowich JR; Story-Remer JH; Wegele A; Richardson SP
    Cortex; 2017 May; 90():115-124. PubMed ID: 28384481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On the role of dopamine replacement therapy in decision-making, working memory, and reward in Parkinson's disease: does the therapy-dose matter?
    Torta DM; Castelli L; Zibetti M; Lopiano L; Geminiani G
    Brain Cogn; 2009 Nov; 71(2):84-91. PubMed ID: 19442427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopaminergic Medication in Parkinson's Disease and Problem Gambling.
    Olley J; Blaszczynski A; Lewis S
    J Gambl Stud; 2015 Sep; 31(3):1085-106. PubMed ID: 25267527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine asymmetry interacts with medication to affect cognition in Parkinson's disease.
    Tomer R; Aharon-Peretz J; Tsitrinbaum Z
    Neuropsychologia; 2007 Jan; 45(2):357-67. PubMed ID: 16876208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parkinson's disease and dopaminergic therapy--differential effects on movement, reward and cognition.
    Rowe JB; Hughes L; Ghosh BC; Eckstein D; Williams-Gray CH; Fallon S; Barker RA; Owen AM
    Brain; 2008 Aug; 131(Pt 8):2094-105. PubMed ID: 18577547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personality, addiction, dopamine: insights from Parkinson's disease.
    Dagher A; Robbins TW
    Neuron; 2009 Feb; 61(4):502-10. PubMed ID: 19249271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reward prediction-errors weighted by cue salience produces addictive behaviours in simulations, with asymmetrical learning and steeper delay discounting.
    Kalhan S; Garrido MI; Hester R; Redish AD
    Neural Netw; 2023 Nov; 168():631-650. PubMed ID: 37844522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrant reward processing in Parkinson's disease is associated with dopamine cell loss.
    Aarts E; Helmich RC; Janssen MJ; Oyen WJ; Bloem BR; Cools R
    Neuroimage; 2012 Feb; 59(4):3339-46. PubMed ID: 22166793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends and issues in characterizing early cognitive changes in Parkinson's disease.
    Claassen DO; Wylie SA
    Curr Neurol Neurosci Rep; 2012 Dec; 12(6):695-702. PubMed ID: 22949166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.